Last Updated: July 10, 2026
Does Medicare Cover Ketamine? Your Options Explained
If you are on Medicare and looking into ketamine therapy for depression, anxiety, or PTSD, what gets covered depends heavily on which type you choose. Medicare does cover Spravato, the FDA-approved nasal spray, but only for people who qualify as treatment-resistant and only when it is given in a certified clinic. The at-home and IV ketamine most people are actually researching fall outside standard coverage. This article explains why that gap exists, what Spravato really costs once you add in clinic visits and monitoring time, and the practical ways to manage out-of-pocket costs for at-home ketamine therapy.
Key takeaways
- Medicare generally does not cover off-label ketamine therapy, including IV infusions and at-home programs, because ketamine is not FDA-approved for mental health conditions.
- At-home ketamine therapy is the lowest per-session option, and superbills, HSA/FSA funds, and payment plans can offset costs that Original Medicare does not reimburse.
- Spravato is the only ketamine-derived therapy Medicare routinely covers, but it is limited to patients who qualify as treatment-resistant, requires in-clinic administration in a REMS-certified facility, and often needs prior authorization.
- Even when covered, Spravato's total cost with coinsurance, clinic visits, and monitoring time may rival or exceed at-home ketamine paid out of pocket.
What Does Ketamine Therapy Mean?
Ketamine is a medication FDA-approved as an anesthetic since 1970 and included on the WHO List of Essential Medicines since 1985.1 The term "ketamine therapy" refers to the use of sub-anesthetic, provider-determined doses of ketamine to address mental health conditions such as depression, anxiety, and PTSD. A Medicare beneficiary will typically encounter three main forms of the treatment.
- IV ketamine infusions: Administered intravenously in a supervised setting, offering high bioavailability but requiring regular in-person visits.
- Spravato (esketamine): An FDA-approved intranasal spray derived from ketamine that must be taken under supervision in a certified provider office.
- At-home ketamine therapy: Prescribed sublingual tablets or subcutaneous injections delivered through telehealth-based programs with clinician oversight. Compounding pharmacies are a regulated, standard component of U.S. healthcare used across many therapeutic areas, not unique to ketamine.2
All three approaches use ketamine or a ketamine derivative but differ in administration route, setting, and FDA approval status. Off-label prescribing is a widespread, legally accepted practice across psychiatry, accounting for approximately 21% of prescriptions.3
- Takeaway: Medicare applies different coverage rules to IV ketamine, Spravato, and at-home ketamine because their FDA approval status, route of administration, and care setting differ. Knowing which type you are considering will clarify what Medicare will and will not cover.
Does Medicare Cover Ketamine Therapy?
Off-label ketamine therapy, including IV infusions, sublingual tablets, and subcutaneous injections prescribed for depression, anxiety, or PTSD, falls outside Medicare's standard coverage. Original Medicare covers services and medications that are FDA-approved for their prescribed indication or meet specific coverage criteria. Because ketamine's FDA approval is limited to anesthesia, its use for mental health conditions is considered off-label.
Medicare's standard benefit structure generally excludes off-label treatments, whether delivered as in-clinic IV infusions or through at-home prescribed ketamine programs. Ketamine infusions for chronic pain are also typically not covered by Medicare for the same off-label reason.
Individual Medicare Advantage plans may have different policies and coverage can vary by state, but standard coverage is rare.
- Medicare Part A: Covers inpatient hospital care and does not apply to outpatient ketamine therapy.
- Medicare Part B: Covers outpatient physician services and FDA-approved medications administered in a clinic, but generally excludes off-label ketamine.
Does Medicare Cover Spravato?
Spravato qualifies for Part B coverage because it holds its own FDA approval for specific psychiatric indications. Spravato is an esketamine nasal spray derived from the S-enantiomer of ketamine. It received FDA approval in March 2019 for treatment-resistant depression, with a supplemental approval in August 2020 for major depressive disorder with acute suicidal ideation or behavior.
Spravato must be administered in a REMS-certified healthcare setting, which requires in-office administration and a minimum two-hour monitoring period. Medicare Part B covers Spravato as an outpatient medical service.
After the annual Part B deductible is met, Medicare typically pays 80% of the approved amount. The beneficiary is then responsible for a 20% coinsurance. A Medigap plan may cover part or all of that remaining 20%.
Prior authorization is often required, which can create logistical hurdles and make the process more labor-intensive for some patients. Medicare Advantage plans may also cover Spravato, but rules, copays, and network restrictions vary by plan. Spravato is currently the only ketamine-derived therapy that Medicare routinely covers, but it requires in-person visits to a REMS-certified facility and involves cost-sharing that can still be significant.
Spravato vs Ketamine for Depression
IV ketamine, Spravato, and at-home prescribed ketamine differ in administration setting, cost, and FDA approval status; cross-study comparisons should still be interpreted with caution because study design, patient populations, and outcome measures vary. Spravato's FDA approval reflects a specific regulatory pathway, not superiority over other forms of ketamine.
IV ketamine is one established method, but requires clinic visits and is not FDA-approved for mental health indications. At-home ketamine therapy offers convenience and lower per-session cost with clinician oversight delivered via telehealth. Each modality represents a different approach for different needs and circumstances.
In addition, coverage is not the same as effectiveness. In the largest head-to-head meta-analysis of the two formulations, racemic ketamine produced roughly 2.2 times the response rate and 2.5 times the remission rate of esketamine (Spravato).4 Spravato is also access-gated in ways the covered price tag does not show: it is approved only for treatment-resistant depression, so patients generally must have already failed other treatments, and it typically requires prior authorization before a plan will pay. For Medicare beneficiaries, Spravato is the only option with standard coverage, but that coverage comes with both an eligibility bar and an effectiveness tradeoff.
| Feature | Spravato (Esketamine) | IV Ketamine | At-Home Ketamine |
|---|---|---|---|
| FDA Approval Status | Approved for specific depression indications | Off-label for mental health | Off-label for mental health |
| Administration Method | Intranasal spray | Intravenous infusion | Sublingual tablet or subcutaneous injection |
| Setting Requirement | REMS-certified clinic | Medical clinic | At home via telehealth |
| Typical Monitoring | 2 hours in-office | 1 to 2 hours in-office | Remote peer treatment monitor |
| Medicare Coverage | Covered under Part B | Generally not covered | Generally not covered |
| Approximate Cost | 20% coinsurance plus clinic fees | Highest per-session cost | Lowest per-session cost |
| Remission Rate | ~18%12 | ~28-30%10,11 | ~28-32%6,7 |
Why Medicare Usually Does Not Cover Ketamine Therapy
The primary reason Medicare does not cover most ketamine therapy is that ketamine is not FDA-approved for psychiatric or pain indications. Medicare's coverage framework is built around FDA-approved uses and established coverage determinations. Three intersecting factors explain the coverage gap.
- Off-label status: Ketamine's only FDA approval is as an anesthetic. Medicare generally does not cover drugs used off-label unless they meet specific compendium-supported criteria or fall under a national or local coverage determination.
- Self-administered drug exclusion: Medicare Part D generally excludes self-administered drugs that are not FDA-approved for the condition being treated. The Part D exclusion directly affects at-home ketamine programs.
- Compounded medication status: Many ketamine providers use compounded formulations. Medicare coverage of compounded drugs is limited and subject to additional restrictions.
The FDA issued a communication in 2023 regarding compounded ketamine products, noting potential risks when used without appropriate oversight.5
- Takeaway: Medicare generally excludes off-label ketamine because ketamine is FDA-approved as an anesthetic, many at-home programs involve self-administered or compounded formulations, and coverage rules are tied to approved indications and plan criteria. Hundreds of peer-reviewed studies support ketamine's therapeutic applications, and off-label prescribing accounts for a significant share of psychiatric medication use.
How Much Does Ketamine Therapy Cost Without Medicare?
When Medicare does not cover ketamine therapy, the full cost falls to the individual. Costs vary significantly depending on the type of ketamine therapy, the provider, and the treatment setting.
- At-home ketamine therapy: Telehealth programs are generally the most affordable per-session option because they eliminate facility overhead and travel.
- Spravato: Even with Medicare Part B coverage, esketamine involves coinsurance plus the cost of regular clinic visits for monitored administration.
- IV ketamine infusions: Intravenous treatments typically carry the highest per-session cost. Patients must also account for travel time and any associated facility fees.
Mindbloom's protocol-driven programs are positioned at approximately 60% less per session than IV ketamine clinics. Clients may be eligible to reimburse a portion of their program cost through major insurance providers or use HSA and FSA dollars. Factor in travel, time off, facility fees, and the number of sessions in a typical course when comparing options.
How to Pay for Ketamine Therapy If You Have Medicare
Several strategies can help reduce out-of-pocket costs even though Medicare generally does not cover off-label ketamine. The following steps apply whether you are considering IV infusions, Spravato, or at-home ketamine therapy.
Step 1: Ask Your Plan What It Covers
Contact your Medicare Advantage or Medigap plan directly and ask whether any related services are covered. Medicare Advantage plans are administered by private insurers and may offer benefits beyond Original Medicare. Your plan might include limited mental health or pain management coverage that could apply.
Ask specifically about Spravato coverage, out-of-network mental health benefits, and any prior authorization requirements. If you also carry private insurance, check that plan's formulary and mental health benefit separately. Kaiser and other large insurers have varying policies on ketamine-related coverage.
Step 2: Request a Superbill for Possible Reimbursement
A superbill is an itemized receipt from your provider that includes diagnosis codes, procedure codes, provider information, and session dates. Many ketamine providers, including at-home programs, can provide superbills. You can submit a superbill to your insurance plan to request out-of-network reimbursement. Reimbursement is not guaranteed and depends on your plan's out-of-network mental health benefits, but it is a common pathway that some clients use to offset costs.
Step 3: Check HSA and FSA Eligibility
Ketamine therapy prescribed by a licensed specialist for a diagnosed medical condition generally qualifies as an HSA and FSA eligible expense. Using pre-tax dollars through these accounts effectively reduces the total cost. Medicare beneficiaries cannot contribute to an HSA after enrolling in Medicare, though they may still spend any existing HSA funds on eligible medical expenses. Those with employer-sponsored coverage may have FSA access, so confirm eligibility with your account administrator.
Step 4: Ask About Payment Plans
Many ketamine providers offer payment plans or financing options that spread the cost across monthly installments. Ask prospective providers about available payment structures before starting treatment. Some at-home programs offer more transparent and predictable pricing than clinic-based infusion centers because the total program cost is defined upfront.
Step 5: Compare In-Clinic vs At-Home Total Costs
Calculate the total cost of care, not just the sticker price per session. In-clinic IV ketamine involves per-infusion fees plus travel costs, time away from work, and potential transportation expenses. Spravato requires regular clinic visits with two-hour monitoring windows.
Mindbloom's at-home programs eliminate travel and facility costs, coming in approximately 60% less per session than IV ketamine clinics. Using the superbill process described in Step 2, clients may seek partial reimbursement through major insurers including Anthem, Aetna, United Healthcare, Cigna, Kaiser, and Blue Cross Blue Shield.
How Clinically Managed At-Home Ketamine Therapy Works at Mindbloom
Responsible at-home ketamine therapy relies on a framework of comprehensive screening, physician oversight, defined protocols, integration support, and ongoing monitoring. Mindbloom has facilitated over 700,000 supervised sessions, making it one of the most evidence-backed implementations of this framework. It is the only at-home ketamine provider offering both sublingual tablets and subcutaneous injections.
Medical Screening and Eligibility
Clients complete an initial assessment and then meet with a licensed prescriber via telehealth for a comprehensive health evaluation. The evaluation covers health history, current medications, psychiatric background, and cardiovascular health to determine whether ketamine is appropriate.
Ketamine therapy may not be appropriate for individuals with uncontrolled hypertension, psychotic disorders, or active substance use disorders. A peer treatment monitor, described in the comparison above, must be present during every session.
Provider-Guided Treatment Plans
Mindbloom offers programs of 6, 12, or 18 sessions. After you select a program, your prescriber confirms eligibility and personalizes your care plan. Mindbloom's at-home ketamine therapy starts at $165 to $215 per session for new clients, depending on program length.
A 6-session program is $215 per session, billed in monthly installments of $430 for 3 months, totaling $1,290. Returning clients pay as little as $129 per session with an 18-session program, or $159 per session for a 6-session program. Each program includes provider consults for ongoing dosage support and progress monitoring.
Treatment frequency is personalized based on individual needs and provider guidance. Mindbloom is the only at-home provider offering subcutaneous administration in addition to sublingual tablets, enabling more consistent dosing.
Preparation and Integration Support
Each client receives guide coaching sessions for preparation and integration, unlimited guide messaging, and unlimited Group Integration Circles. Clients also receive the Bloombox experiential toolkit and access to comprehensive app-guided programs with custom soundscapes.
Preparation and integration are structured components of the program designed to help clients translate the neuroplastic window opened by ketamine into lasting behavioral and emotional change. The integration process is not supplemental; it is core to the treatment model.
Mindbloom Outcomes Research
Building on decades of peer-reviewed research on ketamine's therapeutic applications, Mindbloom has published two of the largest peer-reviewed, real-world outcomes studies of at-home ketamine therapy to date in the Journal of Affective Disorders.6,7 The studies were conducted on Mindbloom clients using the Mindbloom care protocol.
In a peer-reviewed study of 11,441 patients, 89% of clients reported symptom improvement for anxiety and depression.7 Furthermore, 56.4% met criteria for response. Side effects occurred in approximately 4 to 5% of sessions, with serious adverse events in fewer than 0.1%.7 Mindbloom has also published a PTSD preprint demonstrating that 92.2% reported symptom improvement, and a sleep white paper showing a 77% response rate, expanding the research base.8,9
Conclusion
Most ketamine therapy falls outside Medicare's reimbursement framework, though Spravato may qualify under Part B when administered at a REMS-certified facility. For off-label ketamine, superbills, HSA and FSA funds, and payment plans can help manage costs. Defined at-home programs offer clinical rigor with a lower total cost of care. Understanding your options is the first step, and a licensed provider can help determine whether this treatment is appropriate for you.
Important Safety Information
Ketamine is not FDA-approved for PTSD, depression, or anxiety. Common side effects include dissociation, increased blood pressure, nausea, dizziness, and cognitive impairment. Ketamine has abuse potential and is not appropriate for patients with uncontrolled hypertension, psychotic disorders, or substance use disorders. Do not drive or operate machinery until the day after treatment. Individual results may vary. Full safety information: www.mindbloom.com/safety-information
Off-Label Use Disclosure
Ketamine is FDA-approved only as an anesthetic. Use for mental health conditions represents off-label prescribing by licensed clinicians based on clinical judgment. Schedule III Controlled Substance - DEA regulations apply.
Frequently asked questions
Does Medicare Part D cover ketamine lozenges?
Ketamine lozenges and sublingual tablets are generally excluded from Part D because they are self-administered drugs prescribed for off-label use. You will typically need to pay out of pocket or use HSA and FSA funds for at-home ketamine prescriptions.
Will Medicare Advantage pay for IV ketamine infusions?
Off-label IV ketamine infusions for mental health are excluded under most Medicare Advantage plans, which generally follow Original Medicare guidelines. You should contact your specific plan administrator to ask about any exceptions or out-of-network mental health benefits.
How much does Spravato cost with Medicare?
After meeting your annual Part B deductible, Medicare typically covers 80 percent of the approved cost for Spravato, leaving you with a 20 percent coinsurance. A Medigap plan may help cover the remaining out-of-pocket expense.
Can I use a superbill to get Medicare reimbursement for ketamine?
Original Medicare rarely reimburses superbills for off-label ketamine therapy, but some Medicare Advantage plans with out-of-network benefits might offer partial reimbursement. You can submit the itemized receipt to your plan to request coverage.
Does Medicaid cover ketamine therapy?
Medicaid coverage varies significantly by state, but most state programs do not routinely cover off-label ketamine therapy for depression or anxiety. Some state Medicaid programs may cover Spravato when administered in a certified clinic.
Is ketamine therapy considered experimental by Medicare?
Ketamine therapy for mental health is classified as off-label rather than experimental, since ketamine already holds FDA approval as an anesthetic. Medicare often ties outpatient drug coverage to FDA-approved indications, although some off-label uses may qualify for coverage when they meet specific compendium-supported or plan-specific criteria.
Do I need prior authorization for Spravato under Medicare?
Yes, Medicare Part B and Medicare Advantage plans typically require prior authorization before they will cover Spravato treatments. Your healthcare provider must submit documentation showing that you meet the criteria for treatment-resistant depression.
Mindbloom Treatment
Some sort of description will go here about what Mindbloom ketamine therapy actually does and what it promises.
Authors
